ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Share price
+$11.01 (+52.73%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Arcutis Biotherapeutics, Inc. grew revenue 76.1% to $463.98M over the twelve months to Jun 30, 2026. Free cash flow was $39.15M.
Revenue
$463.98M
+76.1% vs. a year earlier
Operating income
$34.25M
TTM Q2 2026
Free cash flow
$39.15M
TTM Q2 2026
EPS, diluted
$0.22
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.33B
- P/E ratio
- 145.0
- Price to sales
- 9.34
- Price to book
- 19.65
- Dividend yield
- –
- Free cash flow yield
- 0.90%
Fundamentals
- Revenue
- $463.98M
- Net income
- $28.52M
- EPS, diluted
- $0.22
- Free cash flow
- $39.15M
- Book value per share
- $1.62
- Diluted shares
- 136M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$463.98M+76.1% YoY
Gross profit
$422.89M+80.2% YoY
Operating income
$34.25M
Net income
$28.52M
EPS, diluted
$0.22
Free cash flow
$39.15M
Reported periodTrailing twelve months